Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event?

Area of Science:

• Cardiovascular Medicine
• Women's Health
• Endocrinology

Background:

• Vascular disease is a primary cause of mortality in women.
• Acute vascular events disproportionately affect women under 60, coinciding with menopausal symptom prevalence.
• Hormone replacement therapy (HRT) is often contraindicated in vascular disease, prompting investigation into its nuanced role.

Purpose of the Study:

• To evaluate the safety and efficacy of HRT in women with pre-existing cardiovascular disease.
• To determine if HRT can be an appropriate treatment option for individual women despite general contraindications.

Main Methods:

• A selective literature search was conducted to synthesize existing data.
• Analysis focused on studies examining HRT use in women with and without cardiovascular or cerebrovascular disease.

Main Results:

• In healthy women, HRT elevates risks of venous thromboembolism and ischemic stroke, particularly >10 years post-menopause or >60 years old.
• Limited data suggest HRT does not increase recurrent vascular events in women with existing cardio/cerebrovascular disease, except possibly in the first year.
• Continuation of HRT post-cardiovascular event shows no association with adverse outcomes.
• Low-dose estradiol, especially transdermal, with neutral progestins, appears to carry a lower risk.

Conclusions:

• While safety data for HRT in cardiovascular event survivors are scarce, a significantly increased risk seems unlikely.
• Off-label HRT initiation or continuation in women with cardiovascular disease necessitates comprehensive counseling on benefits and risks.